| abstract |
The invention relates to CGRP antagonists of general formula (I), in which A, X, D, E, G, M, Q and R<1> to R<3> are defined as in Claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and their salts as well as the hydrates of the salts, particularly their physiologically compatible salts having inorganic or organic acids, to medicaments containing these compounds, to their use, and to methods for the production thereof. |